The top 20 biopharmas demonstrated a strong start to 2025, despite ongoing uncertainty surrounding Trump’s tariffs.

Swiss pharma giant Roche Holding AG RHHBY posted strong growth in the first quarter of 2025. Sales increased 7% year over ...

U.S. pharmaceutical giant Merck has warned that existing tariffs imposed by the Trump administration will cost the company an ...

On the heels of a clinical setback for Bristol Myers Squibb’s schizophrenia newcomer Cobenfy, the New Jersey pharma is ...

With potential tariffs and other drug pricing policies on the horizon, the industry is navigating uncertain waters. | The ...

Norovirus GII.17 variants have overtaken GII.4 as the most prevalent strain and significantly increased norovirus outbreaks in the U.S. and European countries in 2024-2025Cocrystal Pharma's pan-viral ...

Interim Statement on the First Three Months of Financial Year 2025Cohort 7 of the clinical trial of HDP-101 in multiple myeloma safe and well toleratedCohort 8 expected to start soonClinical ...

The Swiss pharma giant made one of the most significant financial promises to bolster its domestic manufacturing capabilities as the Trump administration weighs levying tariffs on drugmakers.

Acquisition will enhance service to healthcare customers needing temperature-controlled solutions in North America.

Here’s what several large drugmakers said about tariffs when reporting earnings this morning: Merck made a small downward ...

Pharmaceutical companies in Europe are requesting the EU to adopt drug pricing strategies comparable to the US.

POTOMAC, MARYLAND / ACCESS Newswire / April 24, 2025 / IGC Pharma, Inc. (NYSE American:IGC) ("IGC" or the "Company") today ...